“A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN-1).” The presentation will describe the ...
Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin Date: September 4, 2025 Time: 4:00 ...
33 rd Annual Meeting of the Diabetic Neuropathy Study Group (NeuroDiab), Sept. 28-Oct. 1; Thessaloniki, Greece; Oral Presentation 59 th Annual Meeting of the European Association for the Study of ...
THE WOODLANDS, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that data from a poster highlighting XERMELO ® (telotristat ethyl) will be ...
Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon ...
THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback